完整後設資料紀錄
DC 欄位語言
dc.contributor.authorChen, Chiao-Chien_US
dc.contributor.authorYao, Nai-Weien_US
dc.contributor.authorLin, Chia-Weien_US
dc.contributor.authorSu, Wei-Shuoen_US
dc.contributor.authorWu, Chin-Tienen_US
dc.contributor.authorChang, Chenen_US
dc.contributor.authorHsieh-Li, Hsiu Meien_US
dc.date.accessioned2020-05-05T00:02:18Z-
dc.date.available2020-05-05T00:02:18Z-
dc.date.issued1970-01-01en_US
dc.identifier.issn1473-4222en_US
dc.identifier.urihttp://dx.doi.org/10.1007/s12311-020-01127-5en_US
dc.identifier.urihttp://hdl.handle.net/11536/154101-
dc.description.abstractSpinocerebellar ataxia (SCA) is a hereditary neurodegenerative disease. We have generated SCA17 transgenic mice bearing human TBP with 109 CAG repeats under the Purkinje cell-specific L7/pcp2 promoter. These mice recapitulate the patients' phenotypes and are suitable for the study of the SCA17 pathomechanism. Magnetic resonance imaging (MRI) and immunostainings were performed to identify the neuroimaging spectrum during disease progression. The results indicate that despite an overall normal appearance at birth, postnatal brain damage takes place rapidly in SCA17. Cerebellar atrophy, fourth-ventricle enlargement, and reduced cerebellar N-acetylaspartate levels were detected at the presymptomatic stage, when the mice were juvenile. The aberrations, which included reductions in body weight; cerebral size; striatal size; and the mean, radial, and axial diffusivities of the cerebellum, became more salient as the disease progressed to the old, late-symptomatic stage. Phosphorylated H2A histone family, member X (gamma H2AX) immunostaining revealed that the cerebellum underwent severe cell senescence in the old stage while the striatum appeared relatively unaffected by aging. Morphometric analysis indicated that the cerebellar atrophy occurred in all subregions with aging. The data establish that the SCA17 mouse brain appears normal at birth but becomes aberrant at the presymptomatic/juvenile stage. More widespread deficits add to the pathological spectrum at the old stage. The study provides information for the expression and expansion of L7/pcp2 promoter and implies the disease progression of SCA17 patients.en_US
dc.language.isoen_USen_US
dc.subjectSCA17en_US
dc.subjectPolyQen_US
dc.subjectMRIen_US
dc.subjectVolumetryen_US
dc.subjectpcp2en_US
dc.titleNeuroimaging Spectrum at Pre-, Early, and Late Symptomatic Stages of SCA17 Miceen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s12311-020-01127-5en_US
dc.identifier.journalCEREBELLUMen_US
dc.citation.spage0en_US
dc.citation.epage0en_US
dc.contributor.department應用數學系zh_TW
dc.contributor.departmentDepartment of Applied Mathematicsen_US
dc.identifier.wosnumberWOS:000524892200003en_US
dc.citation.woscount0en_US
顯示於類別:期刊論文